Dark

AGN
Algernon Pharmaceuticals Inc
stock NYSE

Inactive

May 23, 2025

8.85USD+2.076%(+0.18)54,952

Pre-market

0.00USD0.000%(0.00)0

After-hours

0.00USD0.000%(0.00)0

Overview HistoricalExchangesShortsNews

Jan 25, 2022

02:00AM EST The Hague, January 25, 2022 - Aegon has completed the share buyback program announced on January 7, 2022, in relation to its obligations resulting from the 2021 and 2022 share-based compensation plans for senior management. GlobeNewswire Inc

Jan 7, 2022

02:00AM EST The Hague, January 7, 2022 - Aegon announced today that it will repurchase common shares for an amount of EUR 50 million to meet its obligations resulting from the 2021 and 2022 share-based compensation plans for senior management. The repurchased shares will be held as treasury shares until they are allocated to the plan participants. GlobeNewswire Inc

Dec 22, 2021

04:15PM EST The Hague, December 22, 2021 - Aegon has taken note of an announcement issued today by Vienna Insurance Group AG Wiener Versicherung Gruppe (VIG). GlobeNewswire Inc

Dec 15, 2021

02:00AM EST Aegon reinsures more longevity exposure in the Netherlands GlobeNewswire Inc

Nov 30, 2021

02:00AM EST Aegon to appoint Astrid Jkel as Chief Risk Officer GlobeNewswire Inc

Nov 11, 2021

01:30AM EST Please clickhere to access all 3Q2021results related documents GlobeNewswire Inc

Nov 2, 2021

03:00AM EDT Aegon commits to group-wide net-zero emissions objective by 2050 GlobeNewswire Inc

Oct 27, 2021

02:00AM EDT Aegon completes share buyback program Business Wire

Sep 21, 2021

02:47AM EDT VIG, Aegon To Appeal Against Budapest Metropolitan Court's Ruling On Aegon's Sale Of European Business To VIG RTTNews

02:10AM EDT An update on Aegon's sale of its Central and Eastern European business to VIG Business Wire

Sep 17, 2021

02:13AM EDT Aegon To Repurchase EUR 96 Mln Of Shares To Neutralize Dilutive Effect Of 2021 Interim Dividend Paid In Shares RTTNews

02:00AM EDT Aegon to repurchase shares to neutralize impact of 2021 interim dividend paid in shares Business Wire

Sep 7, 2021

07:30AM EDT Algernon Pharmaceuticals Confirms DMT Increased Growth of Neurons GlobeNewswire Inc

Aug 30, 2021

02:09AM EDT Aegon Bank publishes its first half 2021 report Business Wire

Aug 23, 2021

02:06AM EDT Aegon Closesshare Buyback Program RTTNews

02:00AM EDT Aegon completes share buyback program Business Wire

Aug 19, 2021

07:00AM EDT New ex-dividend and record dates set for the interim dividend 2021 for holders of Aegon's New York Registry Shares Business Wire

Aug 13, 2021

05:19AM EDT Aegon said the European Commission has granted the competition law clearance for the acquisition of the company's businesses in Central and Eastern Europe by Vienna Insurance. VIG is in the process of obtaining all approvals from the national authorities. RTTNews

04:52AM EDT European Commission To Grant Clearance For Acquisition Of Aegon's CEE Businesses By Vienna Insurance RTTNews

04:48AM EDT European Commission gives green light to Vienna Insurance Group for acquisition of Aegon's CEE business Business Wire

Aug 12, 2021

01:30AM EDT Aegon reports second quarter 2021 results Business Wire

01:20AM EDT Aegon calls USD 250 million in perpetual capital securities Business Wire

Aug 11, 2021

07:00AM EDT Algernon Pharmaceuticals Announces Small Cell Lung Cancer GlobeNewswire Inc

Aug 9, 2021

07:00AM EDT Algernon Pharmaceuticals Announces Exclusive Licensing Agreement GlobeNewswire Inc

Jul 7, 2021

12:00PM EDT Aegon to repurchase shares to neutralize impact of 2020 final stock dividend and share-based variable compensation plans Business Wire

07:30AM EDT Algernon Pharmaceuticals Inc.(CSE: AGN) (FRANKFURT: AGW) (OTCB: AGNPF) (the Company or Algernon), a clinical stage pharmaceutical development company, announces that it has reached 70% of its enrollment target for its Phase 2 clinical study of its re-purposed drug NP-120 (Ifenprodil) for idiopathic pulmonary fibrosis (IPF) and chronic cough. GlobeNewswire Inc

Jul 6, 2021

08:30AM EDT Algernon Pharmaceuticals Inc.(CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the Company or Algernon) a clinical stage pharmaceutical development company, announces that it will not be advancing Ifenprodil into a Phase 3 clinical study for COVID-19. GlobeNewswire Inc

Jun 17, 2021

07:00AM EDT Algernon Pharmaceuticals Targets First Human Study of its GlobeNewswire Inc

Jun 15, 2021

02:00AM EDT Allegra van Hvell-Patrizi appointed CEO of Aegon the Netherlands Business Wire

Jun 3, 2021

12:00PM EDT Aegon Annual General Meeting approves all resolutions Business Wire

07:00AM EDT Algernon Pharmaceuticals Launches Pancreatic Cancer Clinical GlobeNewswire Inc

May 27, 2021

07:00AM EDT Algernon Pharmaceuticals Inc.(CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the Company or Algernon) is pleased to highlight an independent research study from the University of Szeged in Hungary describing the use of N,N-dimethyltryptamine (DMT) in improving outcomes in a rat stroke model. A preprint of the study was published on May 20, 2021 in the journal Neuropharmacology. GlobeNewswire Inc

May 17, 2021

07:00AM EDT Algernon Pharmaceuticals Receives Positive Feedback from U.S. FDA GlobeNewswire Inc

May 12, 2021

07:15AM EDT Algernon Pharmaceuticals Announces Ifenprodil Reduced Interleukin GlobeNewswire Inc

01:30AM EDT Aegon reports first quarter 2021 results Business Wire

May 11, 2021

07:01AM EDT Algernon Pharmaceuticals Inc.(CSE: AGN) (FRANKFURT: AGW) (OTCB: BTHCF) (the Company or Algernon) a clinical stage pharmaceutical development company is pleased to announce that it has reached 50% of its enrollment target for its Phase 2 idiopathic pulmonary fibrosis (IPF) and chronic cough clinical study of its re-purposed drug NP-120 (Ifenprodil). GlobeNewswire Inc

02:00AM EDT Maarten Edixhoven to leave Aegon the Netherlands Business Wire

May 10, 2021

02:46AM EDT Aegon Bank Has Set Up An Additional Covered Bond Program RTTNews

Apr 30, 2021

02:00AM EDT Aegon Bank publishes its 2020 annual report Business Wire

Apr 26, 2021

08:00AM EDT Algernon Pharmaceuticals Inc.(CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the Company or Algernon) a clinical stage pharmaceutical development company, announces that it has filed an end of Phase 2 meeting request (EOP2) with the U.S. Food and Drug Administration (FDA), based on the completion of the Phase 2b part of its Phase 2b/3 COVID-19 trial of NP-120 (Ifenprodil). GlobeNewswire Inc

Apr 22, 2021

02:00AM EDT Aegon publishes agenda for 2021 Annual General Meeting Business Wire

Apr 20, 2021

02:00AM EDT Aegon's Global Chief Technology Officer Mark Bloom to step down Business Wire

Apr 13, 2021

02:00AM EDT Elisabetta Caldera joins Aegon as Chief Human Resources Officer Business Wire

Apr 8, 2021

07:00AM EDT Algernon Pharmaceuticals to File End-of-Phase 2 Meeting Request GlobeNewswire Inc

Apr 6, 2021

09:00PM EDT An update of Aegon's sale of its Central and Eastern European business to VIG Business Wire

08:00AM EDT Algernon Pharmaceuticals Announces Appointment of Global Expert Dr GlobeNewswire Inc

Mar 31, 2021

08:00AM EDT Algernon Pharmaceuticals Inc.(CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the Company or Algernon) a clinical stage pharmaceutical development company, is pleased to announce topline data from the Phase 2b part of its Phase 2b/3 COVID-19 trial of NP-120 (Ifenprodil). GlobeNewswire Inc

Mar 29, 2021

07:02AM EDT Algernon Pharmaceuticals Inc.(CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the Company or Algernon) a clinical stage pharmaceutical development company is pleased to announce that it has been added to theHorizons Psychedelic Stock Index ETF (PSYK) in its first quarterly rebalance of holdings. GlobeNewswire Inc

Mar 26, 2021

08:09PM EDT Horizons ETFs Completes Rebalance of World's First Psychedelics ETF PR Newswire

Mar 24, 2021

03:17AM EDT Aegon's Chief HR Officer Carla Mahieu Decides To Step Down, effective June 1, 2021 RTTNews

03:00AM EDT Aegon's Chief Human Resources Officer Carla Mahieu to step down Business Wire

Mar 18, 2021

09:00AM EDT Aegon publishes its 2020 Integrated Annual Report Business Wire

Mar 17, 2021

07:00AM EDT Algernon Pharmaceuticals Submits U.S. FDA Pre-IND Meeting Request GlobeNewswire Inc

Mar 11, 2021

07:41AM EST Algernon Pharmaceuticals Inc.(CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the Company or Algernon), a clinical stage pharmaceutical development company, announces that it expects to report its topline results for the Phase 2b part of its Phase 2b/3 COVID-19 trial of Ifenprodil, in the last week of March 2021. GlobeNewswire Inc

Mar 10, 2021

05:00PM EST Aegon appoints Will Fuller as President and CEO of Transamerica Business Wire

Mar 5, 2021

07:32PM EST Algernon Pharmaceuticals Announces Increase and Close of Private GlobeNewswire Inc

Mar 3, 2021

08:00AM EST Algernon Pharmaceuticals Inc.(CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the Company or Algernon), a clinical stage pharmaceutical development company, is pleased to announce that Algernons CEO Christopher J. Moreau and DMT Consultant Dr. David Nutt DM, FRCP, FRCPSYCH, FSB, FMEDSCI will be discussing the Companys DMT Stroke Clinical Research Program on an upcoming BioPub webcast. GlobeNewswire Inc

Mar 2, 2021

10:18PM EST Algernon Pharmaceuticals Announces Private Placement GlobeNewswire Inc

Mar 1, 2021

08:00AM EST Algernon Pharmaceuticals to Conduct Phase 1 DMT Stroke Program GlobeNewswire Inc

07:00AM EST Algernon Pharmaceuticals Inc.(CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the Company or Algernon) a clinical stage pharmaceutical development company is pleased to announce that it has appointed Dr. Christopher Bryan PhD as Vice President, Research & Operations and Dr. Ahmad Khalil MD, PhD as the Companys Chief Medical Officer. GlobeNewswire Inc

02:06AM EST Aegon Completes Divestment Of Stonebridge RTTNews

02:00AM EST Aegon closes the sale of Stonebridge Business Wire

Feb 25, 2021

07:00AM EST Algernon Pharmaceuticals CEO to Speak at the Psychedelic Capital GlobeNewswire Inc

Feb 19, 2021

08:00AM EST Algernon Pharmaceuticals Inc.(CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the Company or Algernon), a clinical stage pharmaceutical development company, announces that it has awarded the contract to manufacture the active pharmaceutical ingredient and finished product for its formulation of AP-188 (N,N-Dimethyltryptamine or DMT), to Canadian-based Dalton Pharma Services (Dalton). GlobeNewswire Inc

Feb 17, 2021

07:48AM EST Algernon Pharmaceuticals Inc.(CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the Company or Algernon) a clinical stage pharmaceutical development company is pleased to provide an update on the final data set of the Phase 2b part of the Phase 2b/3 COVID-19 Ifenprodil study. GlobeNewswire Inc

Feb 11, 2021

01:30AM EST Aegon reports second half-year 2020 results Business Wire

Feb 10, 2021

12:00PM EST Aegon nominates CFO Matt Rider for reappointment Business Wire

07:00AM EST Algernon Pharmaceuticals Considers Adding Lung Scarring as an GlobeNewswire Inc

Feb 8, 2021

08:05AM EST Algernon Pharmaceuticals Signs Agreement with Charles River GlobeNewswire Inc

Jan 21, 2021

12:29PM EST IIROC Trading Halt - AGN.WT PR Newswire

Jan 7, 2021

08:00AM EST Algernon Pharmaceuticals Inc.(CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the Company or Algernon) a clinical stage pharmaceutical development company, is pleased to provide an overview of the Companys primary plans for the upcoming calendar year. GlobeNewswire Inc

Dec 30, 2020

08:00AM EST Algernon Pharmaceuticals Inc.(CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the Company or Algernon) a clinical stage pharmaceutical development company, is pleased to provide a summary of the Companys key activities this past calendar year. GlobeNewswire Inc

Dec 24, 2020

11:43AM EST Algernon Pharmaceuticals Announces Last Patient Out in GlobeNewswire Inc

Dec 23, 2020

07:41PM EST Algernon Pharmaceuticals Announces Acceleration of Expiry Date of GlobeNewswire Inc

Dec 21, 2020

08:00AM EST Algernon CEO and CSO to Discuss COVID-19 Study Interim Data GlobeNewswire Inc

Dec 17, 2020

08:00AM EST Algernon Pharmaceuticals Inc.(CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the Company or Algernon) a clinical stage pharmaceutical development company, is pleased to provide additional information on its interim data report for the Phase 2b part of the Companys Phase 2b/3 clinical study of Ifenprodil for COVID-19. GlobeNewswire Inc

Dec 16, 2020

07:44PM EST Algernon CEO and CSO to Discuss COVID-19 Interim Data Results GlobeNewswire Inc

Dec 15, 2020

09:30AM EST IIROC Trade Resumption - AGN PR Newswire

08:16AM EST Algernon Pharmaceuticals Inc.(CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the Company or Algernon) a clinical stage pharmaceutical development company, is pleased to report, in a descriptive format, positive trending interim data for the Phase 2b part of the Companys Phase 2b/3 clinical study of Ifenprodil for COVID-19. GlobeNewswire Inc

Dec 14, 2020

02:16PM EST IIROC Trading Halt - AGN PR Newswire

Dec 10, 2020

01:06AM EST Aegon Announces New Strategy And Financial Targets For Period 2021 To 2023 RTTNews

01:00AM EST Aegon Capital Markets Day: Leader in investment, protection, and retirement solutions Business Wire

Nov 30, 2020

08:00AM EST Algernon Pharmaceuticals Announces Enrollment of Final Patient in GlobeNewswire Inc

Nov 29, 2020

04:00AM EST Aegon to sell its Central and Eastern European business to VIG Business Wire

Oct 30, 2020

03:00AM EDT Frans Blom to join Aegon's Supervisory Board Business Wire

Oct 29, 2020

03:24AM EDT Aegon Sells Pyramid Building Complex In San Francisco RTTNews

02:30AM EDT Aegon sells the Pyramid building complex in San Francisco Business Wire

Oct 28, 2020

03:00AM EDT Aegon completes share buyback program Business Wire

Oct 23, 2020

04:52PM EDT Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Allergan plc (NYSE: AGN) between January 30, 2017 and December 19, 2018, inclusive (the Class Period), of the important October 29, 2020 lead plaintiff deadline in the securities class action. The lawsuit seeks to recover damages for Allergan investors under the federal securities laws. GlobeNewswire Inc

Oct 15, 2020

02:15PM EDT Firm Before Important October 29 Deadline in Class Action Seeking Recovery of Investor Losses; Encourages Investors with Losses in Excess of $500K to Contact the Firm - AGN PR Newswire

11:00AM EDT AGN Shareholder Alert - Bronstein, Gewirtz & Grossman, LLC Reminds Shareholders of Class Action Against Allergan plc and New Lead Plaintiff Deadline - October 29, 2020 Business Wire

Oct 9, 2020

10:00AM EDT AGN Investor Alert - Bronstein, Gewirtz & Grossman, LLC Notifies GlobeNewswire Inc

02:20AM EDT Aegon To Divest Stonebridge; Deal Expected To Completed Before End Of 2020 RTTNews

02:00AM EDT Aegon to divest Stonebridge Business Wire

Oct 1, 2020

10:01AM EDT Class Action Against Allergan plc and Lead Plaintiff Deadline - October 29, 2020 PR Newswire

Sep 17, 2020

02:00AM EDT Aegon announces purchase of shares to neutralize 2020 interim stock dividend Business Wire

Sep 14, 2020

02:00AM EDT Jack McGarry to join Aegon's Supervisory Board Business Wire

Sep 11, 2020

02:00AM EDT Aegon Bank publishes first half 2020 report Business Wire

Aug 13, 2020

01:30AM EDT Aegon reports first half 2020 results Business Wire

Aug 5, 2020

02:25PM EDT IIROC Trade Resumption - AGN PR Newswire

01:30PM EDT IIROC Trading Halt - AGN PR Newswire

Jul 30, 2020

03:19AM EDT Aegon And Santander Complete Expansion Of Partnership In Spain RTTNews

Jul 13, 2020

02:00AM EDT Aegon to include Bank in calculation of Group Solvency II ratio Business Wire